New insights into therapy with monoclonal antibodies in allograft transplantation

Nephrology Dialysis Transplantation

Volumn 12, Issue SUPPL. 1, 1997, Pages 55-58

  Schena, F P ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; OKT 3; PENTOXIFYLLINE; T LYMPHOCYTE ANTIBODY;

ASEPTIC MENINGITIS; BONE PAIN; CHILL; CONFERENCE PAPER; DIARRHEA; DYSPNEA; FEVER; HEADACHE; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LUNG EDEMA; MYALGIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; THORAX PAIN; TREMOR; VOMITING;

ANTIBODIES, MONOCLONAL; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031055761     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (29)

1. Koene RAP. Immunosuppression by T cell antibodies in renal transplantation. Nephron 1992; 61: 382-392
2. Bemelman FJ, Buysmann S, Surachno J, Wilmink JM, Schellekens PThA, Ten Berg IJM. Pretreatment with divided doses of steroids strongly decreases side effects of OKT 3. Kidney Int 1994; 46: 1674-1679
3. Alegre ML, Gastaldello K, Abromowicz D, Kinnaert P, Vereerstraeten P, De Pauw L, Vandenabeele P, Maser M, Leo O, Goldman M. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody induced cytokine release syndrome. Transplantation 1991; 52: 674-679
4. Vincenti FG, Vasconcelos V, Birnbaum JL, Tomlanovich SJ, Amend WJ Jr, Melzer JS, Snyder JP. Pentoxifylline reduces the first-dose reactions following OKT 3. Transplant Proc 1993; 25(suppl 1): 57-59
5. De Vault GA Jr, Kohan DE, Nelson EW, Holman JM Jr. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT 3. Transplantation 1994; 57: 532-540
6. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson MR, Heroux AL, Dizikes GJ, Pifarre R, Fisher RI. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recepients. N Engl J Med 1990; 323: 1723-1728
7. Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J, Deeg HJ, Doney K, Thomas D, Storb R, Thomas ED. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784-789
8. Norman DJ, Kimball JA, Bennett WM, Shihab F, Batiuk TD, Meyer MM, Barry JM. A prospective, double blind, randomized study of high-versus low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transplant Int 1994; 7: 356-361
9. Schroeder TJ, First R. Monoclonal antibodies in organ transplantation. Am J Kidney Dis 1994; 23: 138-147
10. Abromowicz D, Goldman M, Mat O, Estermans G, Crusiaux A, Vanherweghem JL, De Pauw L, Kinnaert P, Vereerstraeten P. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. Transplant Int 1994; 7: 258-263
11. Tax WJM, van de Heijden HMW, Willems HW, Hoitsma AJ, Berden JHM, Capel PJA, Koene RAP. Immunosuppression with monoclonal anti-T3 antibody (WT32) in renal transplantation. Transplant Proc 1987; 19: 1905-1907
12. Pfeffer PF, Ohlman S, Jakobsen A, Fauchald P, Leivestad T, Tyden G, Flatmark A. A Scandinavian two-center study of BMA 031 in steroid-resistant rejection of renal grafts. Transplantation 1993; 56: 304-307
13. Waid TH, Lucas BA, Thompson JS, Brown S, Moore D, Amlot P, Janossy G. Treatment of acute cellular kidney allograft rejection with T10B 9. 1A-31 anti-T-cell monoclonal antibody. Transplant Proc 1989; 21: 1778-1784
14. Kirkman RL, Shapiro ME, Carpenter CB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB. Early experience with anti-TAC in clinical renal transplantation. Transplant Proc 1989; 21: 1766-1768
15. Soulillou JP, Cantarovich D, Le Mauff B, Giral M, Hourmant M, Hirn M, Jacques Y. Randomized trial of an anti-interleukin-2 receptor monoclonal antibody (33B3-1) versus rabbit antithymocyte globulin (ATG) in prophylaxis of early rejection in human renal transplantation. N Engl J Med 1990; 322: 1175-1182
16. Hourmant M, Le Mauff B, Cantarovich D, Dantal J, Baatard R, Denis M, Jacques Y, Karam G, Soulillou JP. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results following second kindey transplant. Transplantation 1994; 57: 204-207
17. Cantarovich D, Le Mauff B, Hourmant M, Dantal J, Baatard R, Denis M, Jacques Y, Karam G, Paineau J, Soulillou JP. Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody: I. Results following combined pancreas and kidney transplantation. Transplantation 1994; 57: 190-194
18. Kirkman RL, Shapiro ME, Carpenter CB, McKay DB, Milford EL, Ramos EL, Tilney NL, Waldmann TA, Zimmerman CE, Strom TB. A randomized prospective trial of anti-TAC monoclonal antibody in human renal transplantation. Transplantation 1991; 23: 1066-1067
19. Hiesse C, Kriaa F, Alard P, Lantz O, Noury J, Bensadoun H, Benoit G, Charpentier B, Fries D, Bazin H. Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-TAC-1 with cyclosporin A and steroids in renal transplantation. Transplant Int 1992; 5: 444-450
20. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci 1989; 86: 10029-10033
21. Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293-299
22. Alegre ML, Peterson LJ, Xu D, Satter HA, Jeyarajah R, Kowalkowski K, Thistlethwait JR, Zivin RA, Jolliffe L, Bluestone JA. A non-activating 'humanized' anti CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57: 1537-1543
23. Bastos MC, Pankewycz O, Rubin-Kelly VE, Murphy JR, Strom TB. Concomitant administration of hapten and IL-2-toxin (DAB 486-IL-2) results in specific deletion of antigen-activated T cell clones. J Immunol 1990; 145: 3535-3539
24. Strom TB, Andersen PL, Rubin-Kelley VE, Williams DP, Kiyokawa T, Murphy JR. Immunotoxins and cytokine toxin fusion protein. Ann NY Acad Sci 1991; 636: 233-250
25. Street NE, Mosmann TR. Functional diversity of T lymphocytes due to secretion of different cytokine pattern. FASEB J 1991; 5: 171-177
26. Fitch FW, McKisic MD, Lancki DW, Gajewski TF. Differential regulation of murine T lymphocyte subsets. Annu Rev Immunol 1993; 11: 29-48
27. Nickerson PW, Steurer W, Steiger J, Strom TB. In pursuit of the 'Holy Grail': allograft tolerance. Kidney Int 1994; 45 (suppl 44): S40-S49
28. Naito T, Price D, Bacha P, Nichols J, Strom T, Rubin Kelly V. Interleukin-2 receptor targeted fusion toxins block diabetes in NOD mice (abstract). J Am Soc Nephrol 1994; 5: 970
29. Zheng XX, Steele AW, Stevens AC, Nickerson PW, Tian Y, Strom TB. A noncytolytic IL-10/Fc fusion protein prevents diabetes blocks autoimmunity and promotes suppressor cells in NOD mice (abstract). J Am Soc Nephrol 1995; 6: 859